Abstract
The introduction of erythropoietin (EPO) for the anemia of renal failure has clearly been one of the most important clinical advances in the treatment of end stage renal disease (ESRD). The benefits attributed to EPO use include improvement in cardiac function [1], quality of life [2], cognitive function [3] and increased sexual functioning [4] among others. To accrue these benefits, the hematocrit level is “targeted” to be between 33–36 vols % [5].
Keywords
- Peritoneal Dialysis
- Hemodialysis Patient
- Continuous Ambulatory Peritoneal Dialysis
- Peritoneal Dialysis Patient
- Hematocrit Level
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Pascual J, Teruel JL, Moya JL, Liano F, Jiminez-Mena M, Ortuno J. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: A prospective study. Clin Nephrol. 1991;35:280–7.
Delano EG. Improvements in quality of life following treatment with r-HurEPO in anemic hemodialysis patients. Am J Kidney Dis. 1989;14:S14–18.
Wolcott DL, Marsh JT, La Rue A, Carr C, Nissenson AR. Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. Am J Kidney Dis. 1989;14:478–85.
Schaefer RM, Kobot F, Heidland A. Impact of recombinant erythropoietin in sexual potency in hemodialysis patients: Contrib Nephrol. 1989;76:273–82.
NKF/DOQI Guidelines. Am J Kidney Dis. 2001;37:S186–7.
Sehgal AR. Outcomes of renal replacement therapy among blacks and women. Am J Kidney Dis. 2000;35:S148–52.
US Renal Data System. USRDS 2000 Annual Data Report. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2000.
Greer JW, Milam RA, Eggers PW. Trends in use, cost and outcomes of human recombinant erythropoietin, 1989–1998. Health Care Finance Rev. 1999;20:55–62.
Collins AJ, Li S, Ebben J, Ma JZ, Manning W. Hematocrit levels and associated Medicare expenditures. Am J Kidney Dis. 2000;36:282–93.
Daumit GL, Herman JA, Powe NR. Relation of gender and health insurance to cardiovascular procedure use in persons with progression of chronic renal disease. Med Care. 2000;38:354–65.
Madore F, Lowrie EG, Brugnara C, et al. Anemia in hemodialysis patients: variables affecting this outcome predictor. J Am Soc Nephrol. 1997; 8:1921–9.
Ifudu O, Uribarri J, Rajwant I, et al. Gender modulates responsiveness to recombinant erythropoietin. Am J Kidney Dis. 2001;38:518–22.
Goodnough LT, Price TH, Parvin CA. The endogenous erythropoietin response and the erythropoietic response to blood loss anemia: the effects of age and gender. J Lab Med. 1995;126:57–64.
Rocco MV, Frankenfield DL, Frederick PR, Pugh J, McClellan WM, Owen WF. Intermediate outcomes by race and ethnicity in peritoneal dialysis patients: results from the 1997 ESRD Core Indicator Project. National ESRD Core Indicators Workgroups. Perit Dial Int. 2000;20:328–35.
2000 Annual Report ESRD Clinical Performance Measures Project. Am J Kidney Dis. 2001;37:S28.
Ifudu O, Dawood M, Iofel Y, Valcourt JS, Friedman EA. Delayed referral of black, hispanic and older patients with chronic renal failure. Am J Kidney Dis. 1999;33: 728–33.
Thamer M, Richard CM, Klingmann J, Ivanovich P, Lang G, Cotter DJ. Use of clinical guideline for treatment of anemia among hemodialysis patients. Artif Organs. 2000;24:91–4.
Perry GS, Byers T, Yip R, Margen, S. Iron nutrition does not account for the hemoglobin difference between Blacks and Whites. J Nutrition. 1992; 122:1417–24.
Vasques EM, Beneditti A. Ethnic differences in clinical response to corticosteroid treatment of acute renal allograft rejection. Transplantation. 2001; 71:229–33.
Matthew HW. Racial, ethnic and gender differences in response to medicines. Drug Metabol Drug Interact. 1995;12:77–91.
Cushman WC, Reda, DJ, Perry HM, Williams D, Abjellatif M, Materson BJ. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. VA Cooperative Study Group on Antihypertensive Agents. Arch Intern Med. 2000;27:825–31.
Frackiewicz EJ, Samek JJ, Herrera JM, Kurtz NM, Cutler NR. Ethnicity and antipsychotic response. Ann Pharmacother. 1997;31:1360–9.
Bargman JM, Oreopoulos DG. Complications other than peritonitis or those related to the catheter and the fate of uremic organ dysfunction in patients receiving peritoneal dialysis. In: KD Nolph (ed.), Peritoneal Dialysis, Kluwer Academic Publisher, Boston, p 299. 1989.
Mehta BR, Mogridge C, Bell JD. Changes in red cell mass, plasma volume and hematocrit in patients on CAPD. Trans Amer Soc Artif Intern Organs. 1983;29; 50–2.
Zappacosta AR, Carlo J, Erslev A. Normalization of hematocrit in patients with ESRD on CAPD. Am J Med. 1982;72:53–62.
De Paepe M, Schelstraete K, Ringoir S. Influences of continuous ambulatory peritoneal dialysis on the anemia of endstage renal disease. Kidney Int. 1983;23: 744–8.
Movilli E, Natale C, Cancarini G. Improvements of iron utilization and anemia in uremic patients switched from hemodialysis to continuous peritoneal dialysis. Perit Dial Bull. 1986;6:147–9.
Page DE, House A. Important cost differences of blood transfusions and erythropoietin between hemodialysis and peritoneal dialysis patients. Adv Perit Dial. 1998;14:87–9.
Sezer S, Ozdemir N, Arat Z, et al. What happens after conversion of treatment to continuous ambulatory peritoneal dialysis from hemodialysis? Adv Perit Dial. 2000;16:177–81.
Lopez-Menchero R, Miguel A, Garcia-Ramon R, Perez-Contreras J, Girbes V. Importance of residual renal function in CAPD: its influence on different parameters of renal replacement therapy. Nephron. 1999;83:219–25.
Opatrny K, Opatrna S, Sefrna F, Wirth J. The anemia in continuous ambulatory peritoneal dialysis patients is related to Kt/V index. Artif Organs. 1999;23:65–9.
Ifudu O, Feldman J, Friedman EA. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med. 1996; 334:420–5.
Lacson E, Diaz-Buxo JA. Daily and nocturnal hemodialysis: How do they stack up? Amj Kidney Dis. 2001;38:225–39.
Bonomini V, Miolo V, Albertazzi A, Scolari P. Daily dialysis programme: Indications and results. Proc Eur Dial Transplant Assn. 1972;9:44–52.
Bouncristiani U, Ouintaliani G, Cozzari M, Giombini LRM. Daily dialysis: long term clinical and metabolic results. Kidney Int. 1988;33:S137–40.
Ting G. The effects of daily dialysis on the hematocrit and blood pressure. NIH/ NIDDKD Task Force on Daily Dialysis, Bethesda, MD, 2001:16–17.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Delano, B.G. (2002). Do race, gender or mode of dialysis modulate erythropoietin response?. In: Ifudu, O. (eds) Renal Anemia. Springer, Dordrecht. https://doi.org/10.1007/978-94-015-9998-6_8
Download citation
DOI: https://doi.org/10.1007/978-94-015-9998-6_8
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-6045-7
Online ISBN: 978-94-015-9998-6
eBook Packages: Springer Book Archive